Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: A randomized, double-blind placebo-controlled trial

Antonella Tosti, Matilde Iorizzo, Gian Luca Botta, Massimo Milani

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background: Clinical efficacy of topical corticosteroids in alopecia areata (AA) is still controversial. Positive clinical results have been obtained using ointments with occlusive dressing but this approach has a low patient compliance. Recently, a new topical formulation (thermophobic foam: Versafoam®) of clobetasol propionate 0.05% has been introduced on the market (Olux®, Mipharm, Milan, Italy) (CF). This formulation is easy to apply. After application to the skin the foam quickly evaporates without residues and it has a good patient compliance. In vitro studies have also shown that this formulation enhances the delivery of the active compound through the skin. Aim: To evaluate the efficacy, safety and tolerability of CF in the treatment of moderate to severe AA. Subjects and methods: Thirty-four patients with moderate to severe AA (eight men, mean age 40 ± 13 years) were enrolled in a randomized, double-blind, right-to-left, placebo-controlled, 24-week trial. Alopecia grading score (AGS) was calculated at baseline and after 12 and 24 weeks of treatment using a 0-5 score (0=no alopecia; 5=alopecia totalis). Clobetasol foam and the corresponding placebo foam (PF) were applied twice a day for 5 days/week for 12 weeks (phase 1) using an intrapatient design (right vs. left). From weeks 13 to 24 each enrolled patient continued only with the treatment (both on the right and left site) that was judged to have a greater efficacy than that on the contralateral side (phase 2). The primary outcome of the trial, evaluated on an intention-to-treat basis, was the hair regrowth rate, which was evaluated using a semiquantitative score (RGS) (from 0: no regrowth, to 4: regrowth of ≥ 75%). Results: At baseline the AGS was 4.1 (range: 2-5). Nine (26%) patients prematurely concluded the trial. At the end of phase 1, a greater hair regrowth was observed in 89% of the head sites treated with CF vs. 11% in the sites treated with PF. The RGS was 1.2 ± 1.6 in the CF-treated sites and 0.4 ± 0.8 in the PF-treated sites (P = 0.001). A RGS of ≥2 (hair regrowth of more than 25%) was observed in 42% CF-treated sites and in 13% of PF-treated sites (P = 0.027). In seven subjects (20%) a RGS of 3 to 4 (hair regrowth of ≥50%) was observed in CF-treated sites. In three subjects (9%) a RGS of 4 (hair regrowth of ≥75%) was observed in CF-treated sites. In one patient only, in a PF-treated region, a RGS of 3 was observed. The AS was reduced to 3.8 by CF treatment at the end of phase 1 and to 3.3 at the end of phase 2 (P = 0.01). From weeks 12 to 24 the treatment with CF induced a further increase in the RGS (from 1.2 to 1.5 ± 1.4). Forty-seven per.cent of CF-treated patients had a RGS of ≥ 2 at the end of the trial. A total of eight patients (25%) at the end of the treatment with CF showed a RGS of ≥ 3. Folliculitis occurred in two patients. No significant modifications in cortisol and ACTH blood levels were observed during the trial. Conclusion: This new formulation of clobetasol propionate foam is an effective, safe and well-tolerated topical treatment for AA. This formulation has a good cosmetic acceptance and patient compliance profile.

Original languageEnglish
Pages (from-to)1243-1247
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Volume20
Issue number10
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Clobetasol
Alopecia Areata
Placebos
Hair
Safety
Alopecia
Patient Compliance
Therapeutics
Occlusive Dressings
Folliculitis
Skin
Ointments
Cosmetics
Adrenocorticotropic Hormone
Italy
Hydrocortisone
Adrenal Cortex Hormones
Head

Keywords

  • Alopecia areata
  • Clobetasol
  • Randomized controlled trial

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata : A randomized, double-blind placebo-controlled trial. / Tosti, Antonella; Iorizzo, Matilde; Botta, Gian Luca; Milani, Massimo.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 20, No. 10, 01.11.2006, p. 1243-1247.

Research output: Contribution to journalArticle

@article{8745c57f73e64606a49ad5fdb6c6cffc,
title = "Efficacy and safety of a new clobetasol propionate 0.05{\%} foam in alopecia areata: A randomized, double-blind placebo-controlled trial",
abstract = "Background: Clinical efficacy of topical corticosteroids in alopecia areata (AA) is still controversial. Positive clinical results have been obtained using ointments with occlusive dressing but this approach has a low patient compliance. Recently, a new topical formulation (thermophobic foam: Versafoam{\circledR}) of clobetasol propionate 0.05{\%} has been introduced on the market (Olux{\circledR}, Mipharm, Milan, Italy) (CF). This formulation is easy to apply. After application to the skin the foam quickly evaporates without residues and it has a good patient compliance. In vitro studies have also shown that this formulation enhances the delivery of the active compound through the skin. Aim: To evaluate the efficacy, safety and tolerability of CF in the treatment of moderate to severe AA. Subjects and methods: Thirty-four patients with moderate to severe AA (eight men, mean age 40 ± 13 years) were enrolled in a randomized, double-blind, right-to-left, placebo-controlled, 24-week trial. Alopecia grading score (AGS) was calculated at baseline and after 12 and 24 weeks of treatment using a 0-5 score (0=no alopecia; 5=alopecia totalis). Clobetasol foam and the corresponding placebo foam (PF) were applied twice a day for 5 days/week for 12 weeks (phase 1) using an intrapatient design (right vs. left). From weeks 13 to 24 each enrolled patient continued only with the treatment (both on the right and left site) that was judged to have a greater efficacy than that on the contralateral side (phase 2). The primary outcome of the trial, evaluated on an intention-to-treat basis, was the hair regrowth rate, which was evaluated using a semiquantitative score (RGS) (from 0: no regrowth, to 4: regrowth of ≥ 75{\%}). Results: At baseline the AGS was 4.1 (range: 2-5). Nine (26{\%}) patients prematurely concluded the trial. At the end of phase 1, a greater hair regrowth was observed in 89{\%} of the head sites treated with CF vs. 11{\%} in the sites treated with PF. The RGS was 1.2 ± 1.6 in the CF-treated sites and 0.4 ± 0.8 in the PF-treated sites (P = 0.001). A RGS of ≥2 (hair regrowth of more than 25{\%}) was observed in 42{\%} CF-treated sites and in 13{\%} of PF-treated sites (P = 0.027). In seven subjects (20{\%}) a RGS of 3 to 4 (hair regrowth of ≥50{\%}) was observed in CF-treated sites. In three subjects (9{\%}) a RGS of 4 (hair regrowth of ≥75{\%}) was observed in CF-treated sites. In one patient only, in a PF-treated region, a RGS of 3 was observed. The AS was reduced to 3.8 by CF treatment at the end of phase 1 and to 3.3 at the end of phase 2 (P = 0.01). From weeks 12 to 24 the treatment with CF induced a further increase in the RGS (from 1.2 to 1.5 ± 1.4). Forty-seven per.cent of CF-treated patients had a RGS of ≥ 2 at the end of the trial. A total of eight patients (25{\%}) at the end of the treatment with CF showed a RGS of ≥ 3. Folliculitis occurred in two patients. No significant modifications in cortisol and ACTH blood levels were observed during the trial. Conclusion: This new formulation of clobetasol propionate foam is an effective, safe and well-tolerated topical treatment for AA. This formulation has a good cosmetic acceptance and patient compliance profile.",
keywords = "Alopecia areata, Clobetasol, Randomized controlled trial",
author = "Antonella Tosti and Matilde Iorizzo and Botta, {Gian Luca} and Massimo Milani",
year = "2006",
month = "11",
day = "1",
doi = "10.1111/j.1468-3083.2006.01781.x",
language = "English",
volume = "20",
pages = "1243--1247",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata

T2 - A randomized, double-blind placebo-controlled trial

AU - Tosti, Antonella

AU - Iorizzo, Matilde

AU - Botta, Gian Luca

AU - Milani, Massimo

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Background: Clinical efficacy of topical corticosteroids in alopecia areata (AA) is still controversial. Positive clinical results have been obtained using ointments with occlusive dressing but this approach has a low patient compliance. Recently, a new topical formulation (thermophobic foam: Versafoam®) of clobetasol propionate 0.05% has been introduced on the market (Olux®, Mipharm, Milan, Italy) (CF). This formulation is easy to apply. After application to the skin the foam quickly evaporates without residues and it has a good patient compliance. In vitro studies have also shown that this formulation enhances the delivery of the active compound through the skin. Aim: To evaluate the efficacy, safety and tolerability of CF in the treatment of moderate to severe AA. Subjects and methods: Thirty-four patients with moderate to severe AA (eight men, mean age 40 ± 13 years) were enrolled in a randomized, double-blind, right-to-left, placebo-controlled, 24-week trial. Alopecia grading score (AGS) was calculated at baseline and after 12 and 24 weeks of treatment using a 0-5 score (0=no alopecia; 5=alopecia totalis). Clobetasol foam and the corresponding placebo foam (PF) were applied twice a day for 5 days/week for 12 weeks (phase 1) using an intrapatient design (right vs. left). From weeks 13 to 24 each enrolled patient continued only with the treatment (both on the right and left site) that was judged to have a greater efficacy than that on the contralateral side (phase 2). The primary outcome of the trial, evaluated on an intention-to-treat basis, was the hair regrowth rate, which was evaluated using a semiquantitative score (RGS) (from 0: no regrowth, to 4: regrowth of ≥ 75%). Results: At baseline the AGS was 4.1 (range: 2-5). Nine (26%) patients prematurely concluded the trial. At the end of phase 1, a greater hair regrowth was observed in 89% of the head sites treated with CF vs. 11% in the sites treated with PF. The RGS was 1.2 ± 1.6 in the CF-treated sites and 0.4 ± 0.8 in the PF-treated sites (P = 0.001). A RGS of ≥2 (hair regrowth of more than 25%) was observed in 42% CF-treated sites and in 13% of PF-treated sites (P = 0.027). In seven subjects (20%) a RGS of 3 to 4 (hair regrowth of ≥50%) was observed in CF-treated sites. In three subjects (9%) a RGS of 4 (hair regrowth of ≥75%) was observed in CF-treated sites. In one patient only, in a PF-treated region, a RGS of 3 was observed. The AS was reduced to 3.8 by CF treatment at the end of phase 1 and to 3.3 at the end of phase 2 (P = 0.01). From weeks 12 to 24 the treatment with CF induced a further increase in the RGS (from 1.2 to 1.5 ± 1.4). Forty-seven per.cent of CF-treated patients had a RGS of ≥ 2 at the end of the trial. A total of eight patients (25%) at the end of the treatment with CF showed a RGS of ≥ 3. Folliculitis occurred in two patients. No significant modifications in cortisol and ACTH blood levels were observed during the trial. Conclusion: This new formulation of clobetasol propionate foam is an effective, safe and well-tolerated topical treatment for AA. This formulation has a good cosmetic acceptance and patient compliance profile.

AB - Background: Clinical efficacy of topical corticosteroids in alopecia areata (AA) is still controversial. Positive clinical results have been obtained using ointments with occlusive dressing but this approach has a low patient compliance. Recently, a new topical formulation (thermophobic foam: Versafoam®) of clobetasol propionate 0.05% has been introduced on the market (Olux®, Mipharm, Milan, Italy) (CF). This formulation is easy to apply. After application to the skin the foam quickly evaporates without residues and it has a good patient compliance. In vitro studies have also shown that this formulation enhances the delivery of the active compound through the skin. Aim: To evaluate the efficacy, safety and tolerability of CF in the treatment of moderate to severe AA. Subjects and methods: Thirty-four patients with moderate to severe AA (eight men, mean age 40 ± 13 years) were enrolled in a randomized, double-blind, right-to-left, placebo-controlled, 24-week trial. Alopecia grading score (AGS) was calculated at baseline and after 12 and 24 weeks of treatment using a 0-5 score (0=no alopecia; 5=alopecia totalis). Clobetasol foam and the corresponding placebo foam (PF) were applied twice a day for 5 days/week for 12 weeks (phase 1) using an intrapatient design (right vs. left). From weeks 13 to 24 each enrolled patient continued only with the treatment (both on the right and left site) that was judged to have a greater efficacy than that on the contralateral side (phase 2). The primary outcome of the trial, evaluated on an intention-to-treat basis, was the hair regrowth rate, which was evaluated using a semiquantitative score (RGS) (from 0: no regrowth, to 4: regrowth of ≥ 75%). Results: At baseline the AGS was 4.1 (range: 2-5). Nine (26%) patients prematurely concluded the trial. At the end of phase 1, a greater hair regrowth was observed in 89% of the head sites treated with CF vs. 11% in the sites treated with PF. The RGS was 1.2 ± 1.6 in the CF-treated sites and 0.4 ± 0.8 in the PF-treated sites (P = 0.001). A RGS of ≥2 (hair regrowth of more than 25%) was observed in 42% CF-treated sites and in 13% of PF-treated sites (P = 0.027). In seven subjects (20%) a RGS of 3 to 4 (hair regrowth of ≥50%) was observed in CF-treated sites. In three subjects (9%) a RGS of 4 (hair regrowth of ≥75%) was observed in CF-treated sites. In one patient only, in a PF-treated region, a RGS of 3 was observed. The AS was reduced to 3.8 by CF treatment at the end of phase 1 and to 3.3 at the end of phase 2 (P = 0.01). From weeks 12 to 24 the treatment with CF induced a further increase in the RGS (from 1.2 to 1.5 ± 1.4). Forty-seven per.cent of CF-treated patients had a RGS of ≥ 2 at the end of the trial. A total of eight patients (25%) at the end of the treatment with CF showed a RGS of ≥ 3. Folliculitis occurred in two patients. No significant modifications in cortisol and ACTH blood levels were observed during the trial. Conclusion: This new formulation of clobetasol propionate foam is an effective, safe and well-tolerated topical treatment for AA. This formulation has a good cosmetic acceptance and patient compliance profile.

KW - Alopecia areata

KW - Clobetasol

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=33750300542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750300542&partnerID=8YFLogxK

U2 - 10.1111/j.1468-3083.2006.01781.x

DO - 10.1111/j.1468-3083.2006.01781.x

M3 - Article

C2 - 17062039

AN - SCOPUS:33750300542

VL - 20

SP - 1243

EP - 1247

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 10

ER -